Ecto-CD38-NADase inhibition modulates cardiac metabolism and protects mice against Doxorubicin-induced cardiotoxicity.
Thais R PeclatGuillermo AgorrodyLaura ColmanSonu KashyapJulianna D ZeidlerClaudia Christiano Silva ChiniGina M WarnerKatie L ThompsonPranjali DalviFelipe Cesar BeckedorffSanam EbtehajJoerg HerrmannWim van SchootenEduardo Nunes ChiniPublished in: Cardiovascular research (2024)
Specific and non-cytotoxic ecto-NADase anti-CD38 antibodies may be a potential therapy for anthracyclines-induced cardiac dysfunction.